Abbott Laboratories (ABT)
Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date (Estimated) | 2026-01-21 |
| Earnings Call (Estimated) | 2025-10-15 |
| Avg EPS Estimate | 1.4959 |
| Low EPS Estimate | 1.45 |
| High EPS Estimate | 1.51 |
| Revenue | |
| Avg Revenue Forecast | 11,795,769,800 |
| Low Revenue Forecast | 11,707,600,000 |
| High Revenue Forecast | 11,870,000,000 |
ABT Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $7,733,000,192 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 1.088 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 1.703 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $12,974,999,552 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
ABT Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $11,747,000,320 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $9,118,999,552 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $6,067,874,816 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 56.26% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 19.40% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 31.88% | Net profit margin, which reflects overall profitability. |
ABT Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 25.31% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $12,974,999,552 | Used together with cash and EBITDA to assess debt-paying ability. |
ABT Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 6.90% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for ABT (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $124.54 | Latest stock trading price |
| Price Target (High) | $162 | Analyst highest expected price |
| Price Target (Low) | $122 | Analyst lowest expected price |
| Price Target (Average) | $144.47 | Average target price across analysts |
| Price Target (Median) | $145 | Median of target prices |
| Average Rating Score | 1.76 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 26 | Number of analysts providing estimates |
| Cash Holdings | $7,733,000,192 | Total cash held by the company |
| Cash per Share | $4.45 | Cash value per outstanding share |
| Total Debt | $12,974,999,552 | Company's total debt |
| Quick Ratio | 1.088 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 1.703 | Overall short-term liquidity |
| Debt/Equity Ratio | 25.31% | Leverage ratio: Debt / Equity |
| EBITDA | $11,747,000,320 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $43,842,998,272 | Total company revenue |
| Revenue per Share | $25.189 | Total revenue divided by shares outstanding |
| Gross Profit | 56.26% | Revenue minus cost of goods sold |
| Return on Assets | 6.79% | Net income / Total assets |
| Return on Equity | 30.62% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 6.90% | Year-over-year revenue growth |
| Gross Margin | 56.26% | Gross profit / Total revenue |
| EBITDA Margin | 26.79% | EBITDA / Revenue |
| Operating Margin | 19.40% | Operating income / Revenue |
| Profit Margin | 31.88% | Net income / Revenue |
| Free Cash Flow | $6,067,874,816 | Cash left after capital expenditures |
| Operating Cash Flow | $9,118,999,552 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |